Drug Database
MV

MV-130 (Bactek / MV130)

✓ Approved

Inmunotek · Cell-based Therapies · Cell-based Therapies

What is MV-130?

MV-130 is a cell-based therapies developed by Inmunotek. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesBactek, MV130
CompanyInmunotek
Drug ClassCell-based Therapies, Vaccine
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Inmunotek

Therapeutic Indications

MV-130 is developed for 11 unique indications across 4 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsViral upper respiratory tract infection✓ Approved
Infections and infestationsLower respiratory tract infectionPhase III
Infections and infestationsOtitis mediaPhase II
Infections and infestationsPneumoniaPhase II
Infections and infestationsSinusitisPhase II

+6 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedRespiratory research & clinical practice2026-11-12

Influence of driving pressure and tidal volume on survival of unselected patients requiring mechanical ventilation: a prospective longitudinal study in the ICUs of a quaternary academic medical center in Brazil.

Robira Daniele D, Isensee Larissa Padrão LP, Vilar Marina Lavezzo Dos Santos MLDS, da Silva Fernando Felix FF et al.

To evaluate the association of driving pressure (ΔP) and VT with survival in unselected patients on mechanical ventilation (MV) in a quaternary care hospital in Brazil, as well as whether the initial behavior of ΔP influenced the number of ventilator-free days. This was a single-center prospective cohort study of hospitalized adults across 13 ICUs of an academic medical center in the city of São Paulo, Brazil. We analyzed the first instance of invasive MV ≥ 24 h. Patients were followed for up to 60 days after ICU admission. We used Cox regression to analyze patient survival in relation to ΔP and VT on the first day of MV. The number of ventilator-free days was compared between patients in whom ΔP decreased on the first three days of MV and those in whom ΔP increased or remained stable. A total of 231 patients were evaluated. Of those, 57% were male. The mean age was 55 ± 18 years. The mean Simplified Acute Physiology Score III was 61 ± 17. The median Charlson Comorbidity Index was 3 [IQR, 1-4]. Survival analysis showed that neither ΔP (relative risk = 1.04; 95% CI, 0.08-0.99; p = 0.09) nor VT (relative risk = 0.98; 95% CI, 0.90-1.07; p = 0.66) on the first day of MV affected survival. Disease severity (Simplified Acute Physiology Score III; p < 0.005) and comorbidities (Charlson Comorbidity Index; p < 0.005) were crucial factors for mortality. In our cohort of mechanically ventilated patients with high disease severity and comorbidity burden, neither ΔP nor VT on the first day of MV was associated with survival. No ventilation variable predicted survival, which was primarily determined by disease severity and comorbidities. Changes in ΔP over the first three days were not associated with differences in the number of ventilator-free days.

PMID 43017317
Read full article →
PubMedJDS communications2026-11-12

Comparison of Doppler ultrasound of the milk vein and the Fick principle to estimate mammary plasma flow on the day of calving and at 7 days in milk in multiparous Holstein cows.

Fischer-Tlustos Amanda J AJ, Klein Kayleigh K, Petrou Julia J, McQuaig Cadie C et al.

The aim of this study was to describe the utility of Doppler ultrasonography of the milk vein (MV) to assess mammary plasma flow (MPF) and determine whether a relationship exists between MPF assessed via Doppler ultrasound of the MV (MPFMV) and the Fick principle (MPFFick) on the day of calving and at 7 DIM. A total of 11 parity-2 (P2) and 10 parity-3 (P3) Holstein cows were enrolled in the study immediately after calving. The MPFFick was estimated using the mammary arteriovenous difference of Phe and Tyr as internal markers at 2, 4, 6, and 8 h after colostrum collection and the morning milking at 7 ± 1 DIM. Milk was collected at milking 2 and the evening milking at 7 ± 1 DIM for determination of milk protein output. The MPFMV was also estimated by Doppler ultrasound of the left and right MV at 2 and 8 h after colostrum collection and the morning milking at 7 ± 1 DIM. Both MPFMV and MPFFick increased by 15.8% and 19.5% from calving to 7 DIM, respectively. No differences were detected between parity in MPFFick; however, P3 cows had greater MPFMV than P2 cows, as well as greater MV diameter. No relationship existed between MPFMV and MPFFick during the calving and fresh periods, which may have been due to the violation of multiple assumptions of the Fick principle as a result of the fluctuating rate of milk secretion, tissue metabolism, and blood flow associated with the onset of lactation. Although Doppler ultrasound of the MV may be a time-efficient, noninvasive technique to estimate fresh-period MPF, further work is needed to validate its accuracy with techniques estimating MPF directly in the pudendal artery, such as the dye dilution technique. Such knowledge would allow for the widespread utilization of this noninvasive technique to uncover knowledge gaps pertaining to the relationship between fresh-period mammary metabolism and milk production.

PMID 43016413
Read full article →
PubMedDalton transactions (Cambridge, England : 2003)2026-11-12

{Mo132}-type giant polyoxometalates as electrocatalysts for the hydrogen evolution reaction.

Priya Lakshmi L, Premanand Gopika G, Mondal Partha P, Das Samar K SK

The pressing issues of the exponential growth of the global population and increasing industrialization have led to an unprecedented rise in energy demand, worsening the ongoing energy crisis and environmental concerns associated with fossil fuel consumption. On that account, the development of efficient electrocatalysts for the hydrogen evolution reaction (HER) has emerged as an important research focus for sustainable and clean hydrogen production. This work addresses this issue by reporting an ambient temperature cation exchange reaction of {Mo132} polyoxometalate (POM), leading to the development of three heterogeneous electrocatalysts (LaMo132, EuMo132, and SmMo132) for the HER under mildly acidic conditions. Various spectroscopic, microscopic, and elemental analyses were employed to characterize these compounds. Cation exchange by lanthanide cations (La3+, Eu3+, and Sm3+) rendered {Mo132} water insoluble, thereby enabling the transition from homogeneous to heterogeneous electrocatalysis. The best electrocatalyst, SmMo132, exhibits a Tafel slope of 139 mV per decade with an overpotential of 411 ± 11 mV at 10 mA cm-2.

PMID 43018288
Read full article →
PubMedMaterials horizons2026-11-12

High-performance HfLaO/InGaCdO transistors with gate-controlled dual plasticity.

Wang Wenhao W, Fang Zhengnan Z, Zheng Yingying Y, Lin Wei W et al.

Neuromorphic systems are increasingly moving toward integrating multiple operating modes into a single device. However, existing oxide-based optoelectronic synapses typically rely on pulse strength to switch from short-term plasticity (STP) to long-term plasticity (LTP), which limits the adaptability of a single device to different computational tasks. Here, high-performance HfLaO (HLO)/InGaCdO (IGCO) optoelectronic synaptic transistors are fabricated via full magnetron sputtering, with a steep subthreshold swing (SS) of 96 mV decade-1 and an ultrahigh on/off ratio of 2 × 108. Reversible switching between STP and LTP is realized through gate bias tuning under fixed optical excitation without electrical performance degradation. Stable discrete multilevel conductance states are acquired under an ultralow read voltage of 1 mV and 0.0645 mW cm-2 optical pulses, which supports low-power fully connected neural networks for high-accuracy MNIST handwritten digit recognition. Negative gate bias reproduces typical STP characteristics including paired-pulse facilitation (PPF), and gate-adjustable STP relaxation dynamics construct in-sensor physical reservoirs for temporal signal analysis and four-frame human motion recognition. This all-inorganic oxide transistor exhibits exceptionally high electrical performance and operates at low power, while integrating dual synaptic modes to perform trajectory recognition and speech command recognition. It overcomes the limitations of conventional single-modulation strategies and provides practical hardware solutions for low-power multimodal devices.

PMID 43016364
Read full article →
PubMedACS applied materials & interfaces2026-11-12

Fe-Regulated Sulfidation of Ni-MOF to Construct an Fe-Ni(OH)2/Ni3S2 Heterojunction for Efficient Hydrogen Evolution in Both Acidic and Alkaline Media.

Fang Zhenhua Z, Zheng Fang F, Gaikwad Mayur A MA, Park Youseong Y et al.

Developing efficient and durable non-precious electrocatalysts for the hydrogen evolution reaction (HER) in both acidic and alkaline media is a critical challenge. Herein, we report a Fe-regulated sulfidation strategy that converts a Ni-MOF precursor into a Fe-doped Ni(OH)2/Ni3S2 heterojunction catalyst. Fe acts as a kinetic phase regulator that suppresses the complete conversion of Ni(OH)2 into Ni3S2, stabilizing a mixed phase architecture with abundant heterointerfaces and enlarged electrochemically active surface area. The optimized catalyst delivers exceptional HER performance, requiring overpotentials of only 163.3 mV at -10 mA cm-2 in 1 M KOH and 214.3 mV at -100 mA cm-2 in 0.5 M H2SO4, along with outstanding durability (200 h at -500 mA cm-2 in alkaline electrolyte and 100 h at -100 mA cm-2 in acidic electrolyte). Post-stability characterizations reveal pH-dependent reconstruction: under alkaline conditions, the Ni(OH)2 phase partially dissolves while the Ni3S2 framework remains; under acidic conditions, Fe2+ oxidation to Fe3+ forms a protective M-OH-rich oxide layer on Ni3S2. Density functional theory calculations identify Ni as the primary active site, with Fe functioning as an electronic modulator that redistributes electron density toward Ni and optimizes the d-band center. In alkaline media, the cooperative charge effect and upshifted d-band center synergistically promote water dissociation, with OH* desorption identified as the rate-determining step; in acidic media, strong electrostatic attraction from the highly negatively charged Ni sites dominates H* adsorption. This work highlights the pivotal role of heterojunction engineering and phase regulation in designing durable pH-universal HER catalysts.

PMID 43016245
Read full article →
PubMedJournal of the American Heart Association2026-11-12

Safety and Efficacy of Topical Nitroglycerin for Radial Artery Dilation (The RADial Trial): A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Ullah Waqas W, Janga Chaitra C, Foster Michael M, Nugooru Sudeep S et al.

Transradial coronary catheterization is associated with a reduced risk of bleeding and vascular complications. Prior studies have evaluated nitroglycerin to improve transradial access by vasodilating the radial artery, but the optimal route of administration for preprocedural arterial dilation remains unclear. In the RADial Trial (Radial Artery Dilatation Trial) patients undergoing transradial coronary catheterization were randomized in a double-blind fashion to receive either a placebo or topical nitroglycerin ointment (nitropaste). The primary outcome was the mean change in radial artery dimensions, assessed using paired t tests. Categorical outcomes were analyzed using odds ratio (OR) with 95% CI. A total of 260 patients (130 placebo, 130 nitroglycerin) were enrolled. Nitropaste significantly increased the mean diameter (2.65±0.6 versus 2.48±0.6 mm), circumference (8.37±1.63 versus 7.77±1.66) and cross-sectional area (5.63±2.28 versus 4.94±2.0 mm) of the radial artery, whereas no significant difference was observed in the placebo arm. Nitropaste was associated with a significant reduction in the number of skin punctures and risk of vasospasm (OR 0.34 [95% CI, 0.13-0.91], P=0.04). There was no significant difference between nitropaste and placebo groups in the odds of hematoma (OR, 0.32 [95% CI, 0.03-3.1], P=0.61), crossover to femoral access (OR, 2.29 [95% CI, 0.9-5.8], P=0.12), need for ultrasound-guided access (OR, 0.39 [95% CI, 0.13-1.15], P=0.13), and hypotension or headache (OR, 1.5 [95% CI, 0.24-9.2], P=1.0). Preprocedural administration of nitropaste significantly increases radial artery size and reduces the risk of vasospasm without causing headache or hypotension. https://clinicaltrials.gov/study/NCT05239013.

PMID 43017937
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about MV-130